The latest issue of Financial Standard now available as an e-newspaper
Super-backed company develops COVID treatmentBY ALLY SELBY | WEDNESDAY, 30 SEP 2020 12:26PM
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by up to 96%.
Read more: Ena Respiratory, HESTA, Hostplus, Statewide Super, Brandon Capital, Financial Standard, AustralianSuper, Christophe Demaison, Chris Williams, Medical Research Commercialisation Fund, MH Carnegie, Sam Sicilia, Sonya Sawtell-Rickson
|Sponsored by Praemium|
Bridging the platform gap
|Brought to you by|
|Keep up to date, don't be the last to know! Get the Financial Standard Daily Newsletter.|